AstraZeneca PLC (AZNCF)
130.24
+1.04
(+0.80%)
USD |
OTCM |
Nov 14, 16:00
AstraZeneca Revenue (Quarterly): 12.94B for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 12.94B |
| March 31, 2024 | 12.68B |
| December 31, 2023 | 12.02B |
| September 30, 2023 | 11.49B |
| June 30, 2023 | 11.42B |
| March 31, 2023 | 10.88B |
| December 31, 2022 | 11.21B |
| September 30, 2022 | 10.98B |
| June 30, 2022 | 10.77B |
| March 31, 2022 | 11.39B |
| December 31, 2021 | 12.01B |
| September 30, 2021 | 9.866B |
| June 30, 2021 | 8.22B |
| March 31, 2021 | 7.32B |
| December 31, 2020 | 7.41B |
| September 30, 2020 | 6.578B |
| June 30, 2020 | 6.275B |
| March 31, 2020 | 6.354B |
| December 31, 2019 | 6.664B |
| September 30, 2019 | 6.406B |
| June 30, 2019 | 5.823B |
| March 31, 2019 | 5.491B |
| December 31, 2018 | 6.417B |
| September 30, 2018 | 5.34B |
| June 30, 2018 | 5.155B |
| Date | Value |
|---|---|
| March 31, 2018 | 5.178B |
| December 31, 2017 | 5.777B |
| September 30, 2017 | 6.232B |
| June 30, 2017 | 5.051B |
| March 31, 2017 | 5.405B |
| December 31, 2016 | 5.585B |
| September 30, 2016 | 5.699B |
| June 30, 2016 | 5.603B |
| March 31, 2016 | 6.115B |
| December 31, 2015 | 6.399B |
| September 30, 2015 | 5.945B |
| June 30, 2015 | 6.307B |
| March 31, 2015 | 6.057B |
| December 31, 2014 | 6.716B |
| September 30, 2014 | 6.609B |
| June 30, 2014 | 6.762B |
| March 31, 2014 | 6.46B |
| December 31, 2013 | 6.939B |
| September 30, 2013 | 6.25B |
| June 30, 2013 | 6.232B |
| March 31, 2013 | 6.385B |
| December 31, 2012 | 7.282B |
| September 30, 2012 | 6.682B |
| June 30, 2012 | 6.66B |
| March 31, 2012 | 7.349B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
6.275B
Minimum
Jun 2020
12.94B
Maximum
Jun 2024
9.815B
Average
10.88B
Median
Mar 2023
Revenue (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 128.23M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 5.624M |
| NuCana PLC | -- |
| Autolus Therapeutics PLC | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.927B |
| Total Expenses (Quarterly) | 10.19B |
| EPS Diluted (Quarterly) | 1.24 |
| Enterprise Value | 227.21B |
| Gross Profit Margin (Quarterly) | 83.13% |
| Profit Margin (Quarterly) | 14.89% |
| Earnings Yield | 3.18% |
| Operating Earnings Yield | 4.83% |
| Normalized Earnings Yield | 3.468 |